2 ASX healthcare stocks in good momentum

Healthcare is an attractive sector for investors now due to several structural tailwinds such as ageing populations, rising healthcare spending and continuous innovation in biotechnology and medical treatments.

The sector also benefits from high barriers to entry, intellectual property advantages and the potential for significant upside through clinical breakthroughs and regulatory approvals.
Many ASX healthcare companies operate globally which provides diversified revenue streams and exposure to large international markets.

The following two ASX healthcare stocks now have massive momentum in place for value creation supported by improving fundamentals and key upcoming catalysts.

Cogstate Limited (ASX: CGS) 

Cogstate Limited (ASX: CGS) is among the best ASX healthcare stocks and the stock price rose 12.15% on 8 April after its latest business update which has taken its market capitalisation to $410.3 million.

The company in its 3Q26 update reported exceptional commercial momentum as sales contracts for the quarter reached US$25.4 million which pushed the nine-month total to US$67.1 million.
This figure is much higher than US$41.3 million in FY25 and almost US$27 million in FY24 for the same period which shows rising demand for its solutions.

The company has a strong pipeline because adoption in central nervous system clinical trials is increasing which will support long-term revenue growth.

Demand across CNS indications has expanded and partnerships with pharmaceutical and biotechnology companies have also increased which has improved its global position.
The business model is attractive because it has high returns on capital and the stock has climbed 77.78% over the past 12 months.

The outlook is positive as higher demand for digital cognitive assessments along with strong contract momentum is expected to support steady growth in future.

Clarity Pharmaceuticals Limited (ASX: CU6) 

Clarity Pharmaceuticals Limited (ASX: CU6) is a solid ASX healthcare stock and it surged 6.56% on 8 April while the current market capitalisation is $1.21 billion.
The company as at 31 December 2025 held a cash balance of $226.2 million which was supported by a $203 million capital raise and added R&D tax incentives.

It remains at the clinical stage and does not generate meaningful revenue yet but continues heavy investment in R&D to advance its pipeline of next generation cancer therapies.

Strong clinical progress is visible through key metrics which include multiple Phase III trials such as CLARIFY and AMPLIFY that bring its lead product closer to potential commercialisation.
A major recent update includes a large-scale copper-64 manufacturing agreement with Theragenics which improves supply chain strength ahead of an expected commercial launch.

Several clinical trials are also moving forward with promising efficacy and safety data especially in prostate cancer which can create significant long-term value.

Clarity on the operational side continues to expand its leadership team and build global partnerships which improves execution capability and strengthens strategic position.
The radiopharmaceutical market overall is seeing strong demand because of precision medicine and targeted therapies which supports the company’s long-term growth outlook.

The outlook is positive because strong clinical progress along with a solid balance sheet and upcoming late-stage trial catalysts places the company in a good position for future commercial success.

(Source: Company Announcements)